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Recent genome-wide association studies (GWASs) have identified common genetic variants at 5p15.33,
6p21–6p22 and 15q25.1 associated with lung cancer risk. Several other genetic regions including variants
of CHEK2 (22q12), TP53BP1 (15q15) and RAD52 (12p13) have been demonstrated to influence lung cancer
risk in candidate- or pathway-based analyses. To identify novel risk variants for lung cancer, we performed
a meta-analysis of 16 GWASs, totaling 14 900 cases and 29 485 controls of European descent. Our data pro-
vided increased support for previously identified risk loci at 5p15 (P 5 7.2 3 10216), 6p21 (P 5 2.3 3 10214)
and 15q25 (P 5 2.2 3 10263). Furthermore, we demonstrated histology-specific effects for 5p15, 6p21 and
12p13 loci but not for the 15q25 region. Subgroup analysis also identified a novel disease locus for squamous
cell carcinoma at 9p21 (CDKN2A/p16INK4A/p14ARF/CDKN2B/p15INK4B/ANRIL; rs1333040, P 5 3.0 3 1027) which
was replicated in a series of 5415 Han Chinese (P 5 0.03; combined analysis, P 5 2.33 1028). This large ana-
lysis provides additional evidence for the role of inherited genetic susceptibility to lung cancer and insight
into biological differences in the development of the different histological types of lung cancer.
INTRODUCTION
Lung cancer is a major cause of cancer death worldwide
accounting for over 1 million deaths each year (1). The
major lung cancer histologic subtypes (small cell and non-
small cell) have different clinicopathological characteristics
reflective of differences in carcinogenesis (2).
While lung cancer is largely caused by tobacco smoking, there
is increasing evidence for the role of inherited genetic factors in
disease etiology (3). Notably, genome-wide association studies
(GWASs) of lung cancer have robustly demonstrated that
polymorphic variation at 5p15.33 (TERT/CLPTM1L), 6p21.33
(BAT3/MSH5) and 15q25.1 (CHRNA5/CHRNA3/CHRNB4)
influences lung cancer risk in European populations (4–9).
Additionally, single-nucleotide polymorphisms (SNPs) at
22q12 (10,11) and the 15q15.2 locus containing the
TP53-binding protein 1 gene have been associated with lung
cancer risk (12–14). Three additional susceptibility regions at
13q12.12, 22q12.2 (15) and 3q28 (16) have been identified in
GWASs on Asian populations, but to date these regions
have not been implicated in lung cancer risk in individuals of
European ancestry.
Given the biological differences across lung cancer subtypes,
histology- and smoking-specific associations have been con-
ducted. Analyses have shown that SNP rs2736100 (TERT) is
primarily associated with adenocarcinoma risk (17,18) and vari-
ation in RAD52 at 12p13 with squamous cell carcinoma risk
(19). Significant heterogeneity by smoking status and age of
onset has been shown for SNPs at the 15q25 locus harboring
nicotinic acetylcholine receptor genes (17).
The statistical power of individual GWAS has been limited
by the modest effect sizes of genetic variants, the need to
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establish stringent thresholds of statistical significance and
financial constraints on the numbers of variants that could be
studied. Additionally, due to sample size limitations, few com-
prehensive histology and smoking history subgroup analyses
have been performed in individual GWAS. Meta-analysis
of existing GWAS data therefore offers the opportunity to
discover additional disease loci harboring common variants
associated with lung cancer risk and explore the variability
in genetic effects according to disease heterogeneity.
In this study, we conducted a pooled analysis of data from
16 GWASs of lung cancer providing data on 14 900 cases and
29 485 controls of European ancestry. We studied associations
by histology, sex, smoking status, age of onset, stage and
family history of lung cancer and explored the individual con-
tribution of SNPs in previously identified risk loci. To explore
how these genetic findings translate into non-European popu-
lations, we evaluated selected SNPs in a Han Chinese study of
2338 lung cancer cases and 3077 controls.
RESULTS
A total of 14 900 lung cancer cases and 29 485 controls of
European descent from 16 previously reported lung cancer
GWASs undertaken by nine analytical centers were
included in the meta-analysis (Table 1, Supplementary Mater-
ial, Table S1 and Fig. S1). The meta-analysis was primarily
based on pooling GWAS summary results from 318 094
SNPs featured on Illumina HumanHap 300 BeadChips
arrays. For studies genotyped on HumanHap550 or 610Quad
Illumina platforms, an additional 217 914 SNPs were available
to inform our analysis.
Some degree of genomic over-dispersion (genomic infla-
tion) is expected under a polygenic model even in the
absence of population stratification and other technical arti-
facts (20), and the meta-analysis showed modest evidence of
over-dispersion (l ¼ 1.10) for the core 318 094 SNPs typed
on Illumina HumanHap 300 BeadChips platform (Fig. 1, Sup-
plementary Material, Fig. S2). Adjustment for a genomic infla-
tion factor of 1.10 in this meta-analysis conservatively reduces
the power to detect an association. The l normalized to 1000
cases and 1000 controls was only 1.005, when the approach
proposed by Freedman et al. (21) was applied.
SNPs mapping to the previously identified risk loci at 5p15,
6p21 and 15q25 provided the best evidence for an association
with lung cancer (Supplementary Material, Tables S2 and
S3 and Fig. 1). The strongest association was found for
rs1051730, which maps to exon 5 of CHRNA3 at 15q25
(P ¼ 2.2 × 10263; Fig. 2G), and rs8034191 (r2 ¼ 0.93, D′ ¼
1 between the two SNPs, P ¼ 9.5 × 10259), which is located
in the second intron of the AGPHD1 gene. Consistent with
previous observations (17,18), the rs1051730 association was
significant in smokers (P ¼ 1.8 × 10259) and not in never
smokers (P ¼ 0.06, Fig. 2, Supplementary Material, Fig. S3).
The association also appeared slightly stronger in females
than in males [respective odds ratios (ORs) 1.42 and 1.29,
Phet ¼ 0.02] and for late-stage rather than early-stage disease
(respective ORs 1.39 and 1.28, Phet ¼ 0.06).
Thirty-one additional SNPs localizing to 15q25.1 with a
varied level of linkage disequilibrium (LD) with rs1051730
(Supplementary Material, Table S4) showed a genome-wide
significant association (Supplementary Material, Table S2).
The third strongest evidence for association was observed
for rs6495309 (P ¼ 1.1 × 10232), which maps the 3′ down-
stream of CHRNB4 and shows weaker correlation with
rs1051730 (r2 ¼ 0.15; D′ ¼ 1.00; Fig. 2F). After adjusting
for rs1051730, the effect estimate for rs6495309 was greatly
attenuated (P ¼ 4.0 × 1025), while rs1051730 remained sig-
nificant (P ¼ 2.4 × 10226; Fig. 3) when allele dosage for
rs6495309 was included into a model. Two intronic variants
of CHRNA5 (rs680244, effect allele T, OR ¼ 0.90, P ¼
7.2 × 10210, and rs6495306, effect allele G, OR ¼ 0.91,
P ¼ 1.8 × 1029) changed the direction of effect when control-
ling for rs1051730 (OR ¼ 1.14 P ¼ 1.4 × 1028 and OR ¼
1.13, P ¼ 4.1 × 1028 for rs680244, effect allele T, and
rs6495306, effect allele G, respectively, after controlling for
allelic dosage). Conversely, an analysis adjusting for
rs6495309 enhanced their effects consistently across studies
(P ¼ 9.2 × 10231 and 5.1 × 10232 for rs680244 and
rs6495306, respectively). No other 15q25.1 variant showed a
significant association when allelic dosages for rs1051730
and rs6495309 were included into the statistical model.
After imputation, the most significant association in the
meta-analysis of GWAS data from individuals of European
ancestry was shown by rs951266 (P ¼ 2.8 × 10262, Supple-
mentary Material, Fig. S4), which maps to intron 2 of
CHRNA5 and is in LD with both rs1051730 and rs16969968.
Rs951266 also showed evidence for an association in the Han
Chinese population (MAF¼ 0.04, P, 0.01). Several other
rare imputed variants that do not directly correlate with the
15q25 variants identified in GWAS of European descendants
(r2, 0.05 and D′ ¼ 1) showed association with lung cancer
risk in the Han Chinese population (Supplementary Material,
Fig. S6). These variants map within or in close proximity to
IREB2.
As previously reported (6), two independent susceptibility
variants, rs2736100 and rs401681, which annotate to TERT
and CLPTM1L, were identified in the 5p15.33 region
(Fig. 2A and B). Also consistent with previous findings
(17,18), the risk associated with rs2736100 was largely con-
fined to adenocarcinoma (P ¼ 1.7 × 10219). In contrast,
rs401681 influenced the risk of all lung cancer histologies,
but had its strongest effect on squamous cell carcinoma
(OR ¼ 0.84, P ¼ 3.7 × 10211) and large-cell carcinoma
(OR ¼ 0.78, P ¼ 0.006). Both SNPs in the 5p15.33 locus
had a stronger effect in never smokers (OR ¼ 1.25 for
rs2736100 and OR ¼ 0.80 for rs401681) than in ever
smokers (OR ¼ 1.11, Phet ¼ 0.04 for rs2736100 and OR ¼
0.88; Phet ¼ 0.11 for rs401681). The rs2736100 association
was stronger in women than in men (respective ORs ¼ 1.21
and 1.12; Phet ¼ 0.05) and in late-stage versus early-stage
disease (respective ORs ¼ 1.19 and 1.07; Phet ¼ 0.05). Logis-
tic regression including the allelic dosage of two independent
SNPs (rs401681 and rs2736100) as covariates showed no
support for additional independent associations at 5p15.33
(Fig. 3). Consistent with previous reports (15), rs2736100
and rs401681 both showed an association with lung cancer
risk in Han Chinese (Supplementary Material, Fig. S5). In
the meta-analysis of imputed genotypes, rs2853677, localizing
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to intron 2 of TERT, showed the strongest evidence for an as-
sociation with adenocarcinoma (OR for the G allele ¼ 1.33;
P ¼ 2.2 × 10218) and rs465498, localizing to intron 10 of
CLPTM1L, showed the strongest association with lung
cancer overall (OR for the A allele ¼ 1.15, P ¼ 8.2 × 10218;
Supplementary Material, Fig. S4). Both variants showed corre-
lations with the previously identified SNPs (r2 ¼ 1.0 and D′ ¼
1.0 between genotyped rs401681 and imputed rs465498 at
CLPTM1L and r2 ¼ 0.54 and D‘ ¼ 0.80 between genotyped
rs2736100 and imputed rs2853677 at TERT).
The analysis of previously reported lung cancer risk locus at
6p21–6p22, which encompasses HLA, is complicated by an
extended LD structure (7). The strongest 6p21–6p22 associ-
ation was shown for rs3117582 (P ¼ 2.3 × 10214), which
maps the 5′ upstream of the DNA repair gene BAT3, and is
in complete LD with rs3131379 in MSH5, a DNA mismatch
repair gene. This association was stronger for squamous cell
carcinoma (respective ORs for squamous carcinoma and
adenocarcinoma, 1.30 and 1.12, Phet ¼ 0.02; Fig. 2, Supple-
mentary Material, Fig. S3). Logistic regression including the
allelic dosage of rs3117582 did not identify any SNPs asso-
ciated with lung cancer risk with genome-wide significance
(Fig. 3). When markers were imputed, the strongest signal
for squamous cell carcinoma in this region was observed for
two correlated variants (r2 ¼ 1.0, D′ ¼ 1.0; r2 ¼ 0.76, D′ ¼
0.93 with rs3117582 for both SNPs): rs2523546 (effect
allele G, OR ¼ 0.76, P ¼ 1.1 × 10210) and rs2523571
(effect allele T, OR ¼ 0.76, P ¼ 9.7 × 10211) located in the
3′UTR region of HLA-B (Supplementary Material, Fig. S4).
Excluding SNPs mapping to 5p15.33, 6p21–6p22 and
15q25.1, no SNP showed evidence for a genome-wide signifi-
cant association with lung cancer risk (Fig. 1). Stratification of
lung cancer cases by histology did, however, reveal associa-
tions with squamous cell carcinoma risk for the previously
described risk locus at 12p13 and two potential novel
disease loci at 9p21.3 and 2q32.1 (P , 5.0 × 1027; Figs 1
Table 1. Studies included in the meta-analysis
Study Subjects (n) Location Study design Illumina genotyping
platform
Number of
SNPs
Cases Controls
MDACCa 1150 1134 Texas, USA Hospital-based case–control 317 K 312 829
Liverpool Lung
Project
543 2501 Liverpool, UK Population-bases cases, UK Blood Service
collections controls (UKBS,
WTCCCIIl)
317 K (cases), 1.2 M
(UKBS controls)
283 347
ICR-GWA
studyb
1952 2699 UK Hospital-based cases, 1958 Birth cohort
controls (58C, WTCCCIIl)
550 K (cases), 1.2 M
(58C controls)
283 347
SLRIc/Toronto 331 499 Toronto, Canada Hospital-based case–control 317 K 314 285
IARCd GWAS 312 706
Central
Europe
1854 2453 Romania, Hungary, Slovakia,
Poland, Russia, Czech
Republic
Multicenter hospital-based case–control 317 K, 370Duo
CARETe 394 391 6 US Centers Cancer Prevention Trial 370Duo
Estonia 109 851 Estonia Hospital-based case–control 317 K, 370Duo
France 143 145 Paris Areas, France Hospital-based case–control 370Duo
HUNT2/
Tromsof
394 393 Norway Population-based case–control 370Duo
DeCODE
Genetics
830 11 228 Iceland Population-based case–control 317 K, 370Duo 290 386
HGF Germanyg 487 480 Germany Population-based case–control
(,50 years)
550 K 503 381
Harvard 984 970 Massachusetts, USA Hospital-based case–control 610Quad 543 697
NCI GWAS 506 062
EAGLEh 1920 1979 Italy Population-based case–control 550 K, 610QUAD
ATBCi 1732 1271 Finland Cohort 550 K, 610QUAD
PLCOj 1380 1817 10 US Centers Cohort-Cancer Prevention Trial 317 K + 240 S, 550 K,
610QUAD
CPS-IIk 697 674 All US States Cohort 550 K, 610QUAD
Overall 14 900 29 485
aMD Anderson Cancer Center.
bInstitute of Cancer Research.
cSamuel Lunenfeld Research Institute.
dInternational Agency for Research on Cancer.
eCarotene and Retinol Efficacy Trial cohort.
fNorth Trondelag Health Study 2 / Tromsø IV.
gHelmholtz-Gemeinschaft Deutscher Forschungszentren Lung Cancer GWAS.
hEnvironment And Genetics in Lung cancer Etiology study.
iAlpha-Tocopherol, Beta-Carotene Cancer Prevention study.
jProstate, Lung, Colon, Ovary screening trial.
kCancer Prevention Study II nutrition cohort.
lWellcome Trust Case Control Consortium.
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Figure 1. Manhattan and quantile–quantile (Q–Q) plots for the meta-analysis of lung cancer overall and major histologies. Combined ORs and P-values were derived from the per-allele model. Core 318
094 SNPs corresponding to the Illumina HumanHap 300 BeadChips array are shown in the Manhattan plots as round-shaped. Additional 217 914 SNPs corresponding to the Illumina HumanHap550 array
are shown as triangle-shaped. (A) The Manhattan plot of P-values for the fixed-effects model for the overall meta-analysis. rs1551821 at 18q21.1 reached genome-wide significance for the fixed effect
(effect allele C, OR ¼ 0.81, P ¼ 6.01 × 10210). However, strong heterogeneity by study (Phet ¼ 3.11 × 1026, I2 ¼ 85%) driven by two UK studies (OR ¼ 0.90, P ¼ 0.06 when the ICR removed), observed
deviation from the Hardy–Weinberg equilibrium in the SLRI/Toronto, HGF Germany and MDACC studies and no evidence of association for the correlated SNPs within locus indicated possible chance
finding (Supplementary Material, Fig. S2). (B) The Q–Q plot for P-values in the 2log10 scale for the fixed-effects model for the core 318 094 SNPs. The inflation factor for the 90% bottom SNPs (l) ¼
1.10. The red line represents the concordance of observed and expected values. The shaded area indicates a 99% concentration band. (C) The Manhattan plot of P-values for the fixed-effects model for
adenocarcinoma histology. The inflation factor for the 90% bottom SNPs (l) ¼ 1.05. (D) The Manhattan plot of P-values for the fixed-effects model for squamous cell carcinoma histology. The inflation
factor for the 90% bottom SNPs (l) ¼ 1.04.
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Figure 2. Association between SNPs on 5p15.33, 6p22.3-6p21.31, 9p21.3, 12p13.33 and 15q25.1 and the risk of lung cancer. Combined ORs and 95% CIs were
derived from the per-allele model. Except for the ORs for the random-effects model, results for the fixed-effects model are presented. Squares represent ORs; size
of the square represents the inverse of the variance of the log ORs; horizontal lines represent 95% CIs; diamonds represent the summary estimate combining the
study-specific estimates with a fixed-effects model; solid vertical lines represent OR ¼ 1; dashed vertical lines represent the overall ORs. Results within different
strata (histology, age, smoking, gender, family history and stage) are presented for the fixed-effects model. The allele frequency of selected SNPs by study and
the case–control status are presented in Supplementary Material, Table S7. 1Heterogeneity assessed between ever and never smoking groups. NSCLC,
non-small-cell lung cancer; SCLC, small-cell lung cancer; LCLC, large-cell lung cancer.
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Figure 2. (Continued).
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and 2, Supplementary Material, Fig. S7). No evidence for as-
sociation was noted for chromosome X variants in the gender
subgroup analysis.
Specifically, rs10849605, which maps within intron 1 of the
DNA double-strand repair gene RAD52 in the 12p13.33 region,
was inversely associated with lung cancer risk (effect allele T;
OR ¼ 0.92, P ¼ 5.0 × 1027). This association was particularly
strong among smokers (OR ¼ 0.92, P ¼ 6.0 × 1027) and cases
with squamous (OR ¼ 0.87; P ¼ 6.0 × 1028) and small-cell
carcinoma (OR ¼ 0.85, P ¼ 2.0 × 1026; Phet ¼ 0.0002 across
histologies; Fig. 2E, Supplementary Material, Fig. S3). This
variant was not significantly associated with lung cancer risk
overall or any histology group in the Han Chinese GWAS
(Table 2, Supplementary Material, Fig. S5).
To further explore this region, we performed a
meta-analysis of imputed variants from 15 GWASs from
eight analytical centers on individuals of European ancestry.
In this analysis, rs3748522, which maps to intron 1 of
RAD52 and is in strong LD with rs10849605 (r2 ¼ 0.90,
D′ ¼ 1), provided the strongest association with squamous
cell carcinoma (effect allele A, OR ¼ 0.86, P ¼ 3.4 × 1028;
Supplementary Material, Fig. S4).
The strongest evidence for association at 9p21 was shown
with rs1333040, which is located  74 kb upstream of
CDKN2B, within intron 12 of CDKN1B antisense RNA 1 or
ANRIL (effect allele C, OR ¼ 1.06, P ¼ 9.4 × 1025; Figs 1
and 2D). A subgroup analysis by histology revealed strong
heterogeneity (Phet ¼ 0.003) with the strongest association
for squamous cell cancer (OR ¼ 1.14, P ¼ 2.9 × 1027).
Rs1333040 also showed an association with squamous cell
carcinoma in the Han Chinese population (P ¼ 0.03, Supple-
mentary Material, Fig. S5). In the combined analysis of all
data sets, this association attained genome-wide significance
(P ¼ 2.3 × 1028; Table 2). In an analysis of imputed data
across eight studies, the lowest P-value was shown for
rs1537372 (effect allele G, OR ¼ 1.14, P ¼ 3.3 × 1026)
(r2 ¼ 0.60, D‘ ¼ 0.95 with rs1333040) located in the intron
14 of CDKN1B-AS/ANRIL (Supplementary Material, Fig. S4).
The next strongest association with squamous cell carcin-
oma risk was shown for rs11683501 at 2q32.1 after adjustment
for smoking (effect allele G, OR ¼ 1.17, P ¼ 1.6 × 1027,
Supplementary Material, Fig. S7). This SNP is located 3′
downstream of the nucleoporin 35 kDa (NUP35) gene (22).
Imputation did not identify any stronger association (Supple-
mentary Material, Fig. S4), and rs11683501 did not show an
Figure 3. The regional plot of the 15q25, 5p15 and 6p21–6p22 loci after con-
trolling for most significantly associated SNPs within the locus. P-values for
log-additive association results (2log10) are shown with the recombination
rate based on HapMap phase II data. (A) 15q25 locus. Black dots, results
(2log10 P) for SNPs genotyped within the region. Blue, results after the
inclusion of rs6495309 allele dosage as a covariate; green, results after the in-
clusion of rs1051730 allele dosage as a covariate; red, a model includes allele
dosages for both SNPs. rs7173743 showed association (P ¼ 1.4 × 1025) after
controlling for both SNPs with high heterogeneity between studies I2 ¼
99.1%. (B) 5p15 locus. Black dots, results (2log10 P) for SNPs genotyped
within the region. Blue, results after the inclusion of rs2736100 allele
dosage as a covariate, TERT; green, allele dosage for rs401681 is included
as a covariate, CLPTM1L; red, allele dosages for both SNPs are included as
a covariate. (C) 6p21–6p22 locus. Black dots, (2log10 P) for SNPs genotyped
within the region; green, allele dosage for rs3117582 is included as a covari-
ate, BAG6/BAT3. Two SNPs (rs1003581 and rs130065) reaching genome–
wide significance after conditioning on rs3117582 were observed within the
same locus with strong heterogeneity by study (I2 = 99%) suggesting false
findings.
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association with risk in the Han Chinese population (Supple-
mentary Material, Fig. S5).
We additionally interrogated variation at 15q15.2, which has
been previously identified as a determinant of lung cancer risk
(8,12–14,23). In the meta-analysis, rs504417 showed the stron-
gest association, but did not attain genome-wide significance
(P ¼ 1.2 × 1026; Supplementary Material, Fig. S7).
Finally, we evaluated the 3q28, 2q29, 13q12.12 and 22q12.2
regions previously identified in GWASs of Asian populations
(15,16,24) as risk factors for lung cancer. None of the SNPs
(or their proxies) mapping to these loci showed evidence for
an association in European populations (Supplementary
Material, Table S5).
DISCUSSION
By pooling summary results from 16 GWASs, we have pro-
vided additional evidence for inherited genetic predisposition
to lung cancer and have refined associations at the 5p15,
6p21–6p22, 12p13 and 15q25 risk loci. Furthermore, we
have shown that 9p21.3 variation is a determinant of squa-
mous cell lung cancer risk.
5p15.33 region
Consistent with previous studies (6,7,17,18), our meta-analysis
confirmed two independent signals at 5p15.33 (annotating
TERT and CLPTM1L genes) as determinants of lung cancer
risk impacting differentially on lung cancer histology. The
rs2736100 variant in TERT was principally associated with
adenocarcinoma risk and showed stronger effects in women,
early-onset disease and never smokers where the proportion
of adenocarcinoma cases is generally higher (25–27). Al-
though indirect, the possibility that the association between
rs2736100 and adenocarcinoma risk is mediated through an
effect on TERT is supported by an observation of TERT amp-
lification and mRNA overexpression in adenocarcinoma (28),
as well as the inhibition of lung adenocarcinoma cell growth
promoted by the suppression of hTERT expression (29).
The CLPTM1L association appears stronger in squamous
cell lung carcinoma and large-cell lung cancer, two histology
groups strongly linked to tobacco smoking. This is consistent
with the finding that a variant in CLPTM1L (rs402710, G) has
been associated with high levels of DNA adducts caused by
smoking (30).
6p21–6p22 region
A role for the 6p21–6p22 locus in lung cancer development
has been previously shown by some (4,7), but not all studies
(17,31). This meta-analysis identified 61 SNPs at 6p21–6p22
showing a significant association with lung cancer risk. Most of
these SNPs were highly correlated with rs3117582, which had
the strongest effect for the squamous cell carcinoma. rs3117582
is located 73 bp 5′ of the gene encoding BCL2-associated athano-
gene 6 (BAG6/BAT3), which belongs to a BAG domain contain-
ing a family of proteins that interact with Hsp70/Hsc70 (32).
BAT3/BAG6-deficient mice are embryonic lethal with defects
in the development of the lung, brain and kidney (33). BAT3/T
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BAG6 plays an essential role in p53-mediated apoptosis induced
by genotoxic stress (34). rs3117582 is in perfect LD with
rs3131379, which maps to intron 10 of the DNA mismatch
repair mutS homolog 5 (Escherichia coli) (MSH5) gene. Both
BAT3 andMSH5are expressed in lung tissue and are strong poten-
tial candidates for being the functional basis for the association
(35,36). Since the development of squamous cell lung cancer is
strongly influenced by environmental exposure to carcinogens
that cause DNA damage, it is highly plausible that genetic vari-
ation in the DNA repair mechanism and/or DNA-damage-
induced apoptosis would play an etiologic role.
9p21.3 locus
The 9p21.3 region encodes three tumor suppressor genes that
play key roles in cell cycle inhibition, senescence and stress-
induced apoptosis: CDKN2A/p16INK4A (cyclin-dependent
kinase inhibitors 2A), p14ARF (alternative transcript generated
by alternative exon 1 of CDKN2A/p16INK4A) and CDKN2B/
p15INK4B (cyclin-dependent kinase inhibitors 2B) (37).
CDKN2A/p16INK4A was originally identified as a melanoma
susceptibility gene (38), but is inactivated in many tumors in-
cluding lung cancer (39–42). 9p21.3 variants associated with
lung cancer risk in our study are located 5′ upstream of
CDKN2B, within the intronic region of the CDKN2B antisense
RNA (ANRIL/CDKN2B-AS). Recent studies have demon-
strated 9p21.3 to be a susceptibility locus in many GWASs
(43) including on breast cancer (44), glioma (45,46), type 2
diabetes (47–49), endometriosis (50), coronary artery
disease (51,52), intracranial aneurysm (53) and glaucoma
(44). Several splice variants with varied enhancer activity
have been described for ANRIL (54), including GQ495921,
GQ495919 and GQ495923, which are expressed in lung
cancer cell lines (55). Multiple SNPs, including rs1333040
reported here, have been shown to be associated with ANRIL
mRNA expression in peripheral blood (56). ANRIL recruits a
polycomb repression complex (PRC2) to silence CDKN2B
but not CDKN2A (54,57,58).
The identified SNP rs1333040 correlates (0.7, r2, 0.8) with
24 variants located within or 3′UTR downstream of
CDKN2B-AS. None of these variants are located within the
coding sequence. However, the possibility that the identified
variant is tagging a functional SNP located directly within the
CDKN2A/p16INK4A, p14ARF or CDKN2B/p15INK4B genes cannot
be excluded. Further studies are needed to evaluate the effect
that the SNPs we identified may have on ANRIL/CKDN2B-AS.
12p13.33 locus
The 12p13 risk variants map within the RAD52 homolog gene
which plays a role in DNA double-strand repair and homolo-
gous recombination (59,60). A role of the RAD52 in lung car-
cinogenesis was originally proposed from a candidate gene
study reported by Danoy et al. (61), a finding confirmed by
a pathway-based analysis using GWAS data from the National
Cancer Institute (NCI), UK, and the MD Anderson Cancer
Center (MDACC) studies which robustly demonstrated an as-
sociation for squamous lung cancer (19). The role of RAD52 in
repairing double-strand breaks induced by tobacco smoking is
supported by the association being confined to smokers.
15q25.1 region
The present study has confirmed the smoking-related effect of
15q25 variation on lung cancer risk and has provided addition-
al support for the existence of several independent disease loci
within the CHRNA5/CHRNA3/CHRNB4 region. This is con-
sistent with genotyping data which has shown several distinct
signals for smoking behavior and lung cancer risk within this
region (62–64). Saccone et al. (63) described four distinct loci
influencing smoking behavior at 15q25 with at least two of
them (locus 1 annotated by rs1051730/rs16969968 and locus
3 annotated by rs588765) having independent effects on
smoking behavior. The second locus annotated by rs6495308
was more strongly associated with heavy smoking. In contrast,
the Oxford-GlaxoSmithKline study reported a secondary locus
distinct from rs6495308 (62).
Our current study supports the existence of the two distinct
signals defined by rs1051730/rs16969968 and rs6495309/
rs6495308/rs2036534. Reciprocal attenuation of the effects
for these two signals when allele dosage for an opposite
variant is included into a model raises the possibility of an
underlying haplotypic effect (r2 ¼ 0.17, D′ ¼ 1.0 between
these two SNPs) or an imperfect correlation with an
unknown functional variant. We also observed an effect for
rs680244/rs6495306 (r2 ¼ 1.0, D′ ¼ 1.0 with rs588765 for
both) in our meta-analysis, which remained significant at a
genome-wide level when controlled for rs6495309 and strong-
ly diminished when controlled for both rs1051730 and
rs6495309. This suggests that the rs588765/rs680244/
rs6495306 effect on lung cancer risk is not independent.
Similar to the earlier observation from Saccone et al. (63),
these variants had opposite effects when adjusted for
rs1051730, which may reflect a haplotypic organization in
which the rs1051730 allele increases risk while other asso-
ciated SNPs decrease the risk.
Impact of variants on squamous cell carcinoma
and adenocarcinoma
Our study confirmed a different genetic background for the
two major histological subtypes of lung cancer—squamous
cell carcinoma and adenocarcinoma. Although the role of
the CHRNA5/CHRNA3/CHRNB4 locus at 15q25 and, to
some extent, the CLPTM1L locus at 5p15.33 appeared inde-
pendent from the histology type, all other identified genomic
regions showed strong heterogeneity by histology, suggesting
different genetic etiologies for these lung cancer subtypes. The
significance of cell cycle control (CDKN2A/ARF/CDKN2B/
ANRIL), DNA damage response and DNA repair genes
(RAD52 and BAT3/MSH5) in squamous cell carcinoma is con-
sistent with the notion of a particularly strong effect of
smoking on the development of this histological subtype
(65) and suggests candidate drug targets that may have clinical
utility (66).
The power of the meta-analysis to identify 5p15.33, 6p21–
6p22 and 15q25.1 risk SNPs and loci was over 90%, making it
unlikely that additional lung cancer susceptibility variants of
similar magnitude and allele frequencies can be identified
by simply increasing sample size in Europeans. In contrast,
the power of our study was limited to detect rarer variants
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(i.e. MAFs , 0.05) and common variants of a small effect
size (i.e. RR ≤ 1.05) and/or with modest effects confined to
a specific histology (Supplementary Material, Fig. S8). The
present study was also limited to the genetic variants tagged
by the genotyping arrays used. Several novel variants were
identified within 5p15.33, 6p21–6p22, 9p21.3, 12p13.33 and
15q25.1 through imputation. The imputed variants correlated
with the previously genotyped SNPs in individuals of Euro-
pean descendents, suggesting no additional independent
signal within known loci to be identified. However, the repli-
cation of imputed variants by direct genotyping would be
helpful to completely characterize the strength of effects of
these SNPs.
In summary, by pooling results from 16 GWASs, we have
been able to comprehensively assay the relationship between
common genetic variation and lung cancer risk. Furthermore,
we have been able to demonstrate a novel relationship
between 9p21.3 variation and squamous cell lung carcinoma.
This study provides valuable insights into the pathogenesis of
lung cancer, indicating that there is etiological heterogeneity
to disease development which is influenced by inherited
genetic variation. The identification of additional risk loci
is likely to require genotyping larger series using arrays
formatted to capture variants poorly tagged by current
platforms.
MATERIAL AND METHODS
The study was conducted under the auspices of the Transdis-
ciplinary Research In Cancer of the Lung (TRICL) Research
Team, which is a part of the Genetic Associations and
MEchanisms in ONcology (GAME-ON) consortium, and
associated with the International Lung Cancer Consortium
(ILCCO).
Description of studies
The meta-analysis was based on summary data from 16 previ-
ously reported lung cancer GWASs undertaken by nine analyt-
ical centers providing genotype data on 14 900 lung cancer
cases and 29 485 controls of European descent: the MD An-
derson Cancer Center lung cancer study (5); cases from the
Liverpool Lung Project and control individuals from the UK
Blood Service collections (UKBS) (4,67); the UK lung
cancer GWAS from the Institute for Cancer Research includ-
ing lung cancer cases from the Genetic Lung Cancer Predis-
position Study (GELCAPS) and controls from the 1958
Birth Cohort (7,68,69); the deCODE Genetics lung cancer
study (9); the Helmholtz-Gemeinschaft Deutscher Forschungs-
zentren (HGF) lung cancer GWAS (70); the lung cancer study
from Canada (University of Toronto and Samuel Lunenfeld
Research Institute) (4); the Harvard lung cancer study (71);
the NCI lung cancer GWAS including the Environment and
Genetics in Lung Cancer Etiology (EAGLE) study (72), the
Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study
(ATBC) (73), the Prostate, Lung, Colon, Ovary Screening
Trial (PLCO) (74) and the Cancer Prevention Study II Nutri-
tion Cohort (CPS-II) (18,75); the IARC lung cancer GWAS
(4) including Central Europe GWAS (76), the Carotene and
Retinol Efficacy Trial (CARET) cohort lung cancer GWAS
(77), the HUNT2/Tromso 4 study (78), lung cancer GWAS
from France (79) and the lung cancer study from Estonia
(80,81) (Table 1; Supplementary Material, Material and
methods). All participants provided informed written
consent. All studies were reviewed and approved by institu-
tional ethics review committees at the involved institutions.
In each of these studies, SNP genotyping had been performed
using Illumina HumanHap 300 BeadChips, HumanHap550 or
610 Quad arrays. Further details about selection criteria,
cancer diagnosis, genotyping and quality control in each
study are provided in the Supplementary Material, Material
and methods. Lung cancer diagnosis in most studies was
based on histopathology or cytology but in a minority on clin-
ical history and imaging.
The Chinese lung cancer GWAS included 2338 lung cancer
cases and 3077 controls from the Nanjing and Beijing Lung
Cancer Studies (15) genotyped using Affymetrix Human
SNP Array 6.0 chips (Supplementary Material, Material and
methods). The Nanjing and Beijing Lung Cancer Studies pro-
vided summary data on the top SNPs for overall lung cancer
risk and risk by specific histology. The selected loci were
5p15.33 (1.20–1.61 Mb), 6p22.3–6p21.31 (22.0–36.5 Mb),
15q25.1 (76.1–77.2 Mb), 18q2.3 (40.0–21.5 Mb), 12p13.33
(0.54–1.54 Mb), 2q32.1 (183.4–184.5 Mb) and 9p21.3
(21.66–22.2 Mb) (NCBI Build 36).
Statistical methods
Study-specific analysis of GWAS data
Associations between SNP genotypes and lung cancer risk were
evaluated under a log-additive model of inheritance. Addition-
ally, we explored dominant, recessive and co-dominant
models. Each study center provided summary statistics from
two models: (i) unconditional logistic regression adjusted for
sex, age at diagnosis or age at recruitment (5-year age intervals),
country/study center where appropriate and significant principal
components for population stratification and (ii) additionally
adjusted for smoking status coded as categorical variable
never/current/former. Analyses stratified by histology (adeno-
carcinoma, squamous cell carcinoma, large-cell carcinoma
and small-cell carcinoma), sex, age at diagnosis for cases or re-
cruitment for controls (≤50 and .50 years), smoking status
(current, former, never), tumor stage (I–IV) and family
history of lung cancer in a first-degree relative were performed
(Supplementary Material, Table S1). Both the UK studies did
not contribute data to the smoking analysis, since this informa-
tion was not available for controls. In addition to the above ana-
lyses, each centre provided lung cancer risk estimates for 15q25,
6p21 and 5p15 loci after controlling for allelic dosage for the
most significantly associated SNP(s) within the locus. For the
15q25 locus, the statistical model included rs1051730 and/or
rs6495309 allelic dosages as covariates; for the 6p21 locus,
rs3117582 allelic dosage and for the 5p15 locus allelic,
dosages for rs401681 and/or rs2736100.
Prior to undertaking the meta-analysis of all GWAS data
sets, we searched for potential errors and biases in data from
each case–control series (82). With the exception of the Liv-
erpool Lung Project, quantile–quantile (Q–Q) plots showed
that there was minimal inflation of the test statistics, indicating
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that substantial cryptic population substructure or differential
genotype calling between cases and controls was unlikely in
each of the GWASs (Supplementary Material, Fig. S1).
Imputation
To refine the association of the previously reported and newly
identified disease loci, we imputed untyped genotypes using
Impute2 (83), Mach1 (84,85) or minimac (86) software and
HapMap Phase II, Phase III and/or 1000 Genome Project
data release 2010-08 or 2010-06 reference genotypes (Supple-
mentary Material, Table S6). The selected loci were 5p15.33
(1.20–1.61 Mb), 6p22.3–6p21.31 (22.0–36.5 Mb), 15q25.1
(76.1–77.2 Mb), 18q2.3 (40.0–21.5 Mb), 12p13.33 (0.54–
1.54 Mb), 2q32.1 (183.4–184.5 Mb) and 9p21.3 (21.66–
22.2 Mb) (NCBI Build 36). The analytical scheme was
similar to the meta-analysis but taking imputation uncertainty
into account by using posterior means or allele dosage in lo-
gistic regression. Imputed allele dosage for each SNP was
tested for association with lung cancer risk using the two
models with and without adjustment for smoking as described
above. The meta-analysis of imputed genotypes included all
studies except the HGF Germany where imputed data were
not available. Poorly imputed SNPs defined by an RSQR,
0.30 with MACH1/minimac or an information measure Is ,
0.30 with IMPUTE2 were excluded from the analyses (Sup-
plementary Material, Table S6).
Meta-analysis
The meta-analysis was primarily based on pooling GWAS
results for the log-additive model of inheritance from 318
094 SNPs featured on Illumina HumanHap 300 BeadChips
arrays. For studies genotyped on HumanHap550 or 610Quad
Illumina platforms, additional 217 914 SNPs were available
to inform our analysis.
Meta-analysis under fixed and random-effects models was
conducted. As with individual studies, we examined for the
over-dispersion of P-values in the meta-analysis by generating
Q–Q plots and deriving an inflation factor l by comparison of
observed versus expected P-values for the meta-analysis ap-
plying the estlambda function within the GenABEL package
(87). Cochran’s Q statistic to test for heterogeneity and the
I2 statistic to quantify the proportion of the total variation
due to heterogeneity were calculated. I2 values ≥75% are con-
sidered the characteristic of large heterogeneity (88). To assess
the robustness of associations in the meta-analysis, we per-
formed a sensitivity analysis sequentially excluding studies.
Wherever removing one study resulted in a .10% change
of the OR point estimates, we reported results separately (89).
All calculations were performed using PLINK (90) and SAS
version 9.2 (SAS Institute Inc., Cary, NC, USA). Q–Q and Man-
hattan plots were created using an R library GenABEL (87). We
used LocusZoom for regional visualization of results (91).
Power calculations were performed using QUANTO version
1.2.4 for the main effect of gene and the log-additive model
of inheritance stipulating a P-value of 5.0 × 1028 (92).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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